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Muscle and bone are closely associated in both anatomy and
function, but the mechanisms that coordinate their synergistic
action remain poorly defined.Myostatin, a myokine secreted by
muscles, has been shown to inhibit muscle growth, and the dis-
ruption of themyostatin gene has been reported to causemuscle
hypertrophy and increase bone mass. Extracellular vesicle-exo-
somes that carry microRNA (miRNA), mRNA, and proteins are
known toperforman important role in cell-cell communication.
We hypothesized that myostatin may play a crucial role in mus-
cle-bone interactions and may promote direct effects on osteo-
cytes and onosteocyte-derived exosomalmiRNAs, thereby indi-
rectly influencing the function of other bone cells. We report
herein that myostatin promotes expression of several bone reg-
ulators such as sclerostin (SOST), DKK1, and RANKL in cul-
tured osteocytic (Ocy454) cells, concomitant with the suppres-
sion of miR-218 in both parent Ocy454 cells and derived
exosomes. Exosomes produced byOcy454 cells that had been pre-
treated with myostatin could be taken up by osteoblastic MC3T3
cells, resulting in a marked reduction of Runx2, a key regulator of
osteoblasticdifferentiation, and indecreasedosteoblasticdifferen-
tiation via the down-regulation of the Wnt signaling pathway.
Importantly, the inhibitoryeffectofmyostatin-modifiedosteocytic
exosomes on osteoblast differentiation is completely reversed by
expressionof exogenousmiR-218, throughamechanism involving
miR-218-mediated inhibition of SOST. Together, our findings
indicate that myostatin directly influences osteocyte function and
thereby inhibits osteoblastic differentiation, at least in part,
through the suppression of osteocyte-derived exosomal miR-218,
suggesting a novel mechanism inmuscle-bone communication.
Muscle and bone form a functional unit that undergoes
changes of mass in a coordinated, usually symmetrical, manner
(1, 2). Mechanical loading of bone bymuscle is one of the larger
sources of load experienced by the skeleton; muscle mass is
closely correlated with bone mass, suggesting an essential role
of muscle activity in maintaining a balance between bone for-
mation and bone resorption (3–5). Trained athletes, especially
those who engage in weight-dependent activities, often have
greater muscle and bone mass and strength than individuals
who are less physically active (6). It is reported that in the
United States among older adults with an average age of 70
years, the prevalence of sarcopenia is 36.5% (7). Sarcopeniawith
decline in skeletal muscle mass and function has been linked to
senile osteoporosis (8). Particularly, extreme immobilization,
such as that after spinal cord injury, leads to marked bone loss
and muscle paralysis (9–13). However, the mechanisms by
which muscle interacts with bone to determine mass and func-
tion remain poorly defined.
Comprising 95% of total bone cells, osteocytes are deeply
embedded in cave-like lacunae in the bone matrix (14–16).
Osteocytes have many dendritic processes extending through
canaliculi to form a highly connected communication network
between themselves and also between osteoblasts and oste-
oclasts at the bone surface (17). Osteocytes are widely believed
to be a principal mechanosensor of bone that is able to respond
to mechanical stimuli, transducing load signals into anabolic
chemical signals to recruit osteoblasts and osteoclasts (15, 17,
18). Osteocytes are the major source of sclerostin and receptor
activator of nuclear factor B ligand (RANKL),2 two of the
major signals in bone metabolism (19–21). As such, osteocytes
have been considered an orchestrator of bone remodeling and
mineral metabolism (15, 22). Recent work has revealed that
muscle may positively or negatively influence bone growth by
secreting osteogenic myokines, such as insulin-like growth fac-
tor 1 (IGF1), fibroblast growth factor 2 (FGF2), irisin, andmyo-
statin (23–26). However, it remains unknown as to whether
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these myokines exert a direct effect on osteocytes and, if so, the
mechanisms of action.
Myostatin, a hormone secreted by muscles and a member of
the transforming growth factor superfamily of growth factors,
has been shown to inhibit muscle differentiation and growth
(27–29). Myostatin activates signaling upon binding to the
activin receptor IIB (ActRIIB), ultimately resulting in Smad2/3
phosphorylation followed by translocation to the nucleus to
modulate transcription of numerous genes (30). Myostatin can
increase during sarcopenia, cancer, infection, traumatic mus-
culoskeletal injury, and bed rest, whereas resistance training
decreases myostatin levels (2, 31–33). The absence of the myo-
statin gene in knock-outmicemodels not only increasesmuscle
mass but also tends to result in an increase in bone density and
strength (28). As such, the study ofmyostatin provides a unique
opportunity to elucidate the mechanisms by whichmuscle reg-
ulates bone cell function and, hence, bone substance. Inhibition
of myostatin by a soluble activin IIB receptor leads to increased
bone formation in mice (34). It is possible that factors released
frommuscle, such asmyostatin or othermyokines,may directly
or indirectly modulate secretory products of osteocytes that
may then alter the function of osteoblasts and osteoclasts.
Exosomes are extracellular organelles (30–100 nm in size)
that are released by cells by exocytosis and engulfed by cells
through phagocytosis. Exosomes play an important role in
intercellular communication and have pleiotropic effects on
physiological functions of neighboring cells (35–38). Exosomes
carry proteins, mRNA, and microRNA (miRNA) (37). miRNA
is a single-stranded non-protein-coding RNA that binds to the
target messenger RNA and functions primarily as a gene
repressor. Thus, exosomes are considered to have regulatory
functions through its component miRNA (37, 38). Emerging
evidence indicates that miRNAs play important roles in regu-
lating osteoclast and osteoblast function (39). During osteo-
blast differentiation, the miR-218 gene is induced and acts to
promote the differentiation of undifferentiated bone marrow
cells by stimulating the Wnt signaling pathway through the
inactivation of Wnt inhibitors sclerostin (encoded by SOST
gene), dickkopf WNT signaling pathway inhibitor 2(DKK2),
and secreted frizzled-related protein 2 (sFRP2) (40). Oste-
oclast-derived exosomalmiR-214-3p transfers to osteoblasts to
inhibit bone formation (41). Recent observation suggested that
osteocytes shedmicrovesicles containing not-yet-defined bone
regulatory factors that may induce osteoblast differentiation.3
Thus, it is likely that myostatinmay exert a role inmuscle-bone
communication by regulation of the release of exosomal
miRNAs from osteocytes.
Wnt/-catenin signaling pathway is a key determinant of
bone mass by controlling bone formation and bone resorption
(14, 43–46). Sclerostin and DKK1 act by binding to the Wnt
co-receptors LRP5/6 to inhibitWnt signaling, thereby contrib-
uting to bone loss (15). Osteoclastogenesis and osteoclast activ-
ity are regulated by RANKL and osteoprotegerin (OPG); specif-
ically, RANKL activates osteoclast differentiation, whereas
OPG reduces the activity of RANKL (46–48). We recently
reported that electrically stimulated muscle contraction
reverses elevations in bone resorption and increases Wnt sig-
naling in bone-derived cells after spinal cord transection (49).
Interestingly, injection of irisin profoundly stimulates cortical
bone mass and strength in mice accompanied by dramatically
increased osteoblastic bone formation and diminished osteo-
blast inhibitors, such as SOST (25). Moreover, the activation of
Wnt/-catenin signaling is widely believed to be a critical com-
ponent of mechanotransduction that is orchestrated by the
osteocyte (15). Of note, secreted factors by muscle cells have
recently been shown to preserve osteocyte viability through the
activation of -catenin (50).
Hence, we hypothesized that (i) myostatin, and possibly
other muscle-related factors, may play a essential role in mus-
cle-bone interaction that is mediated through the action(s) of
the osteocyte, (ii) myostatin has a direct effect on the osteocyte
and osteocytic-derived exosomal miRNAs, thereby indirectly
influencing the function of the osteoblast and the osteoclast,
and (iii) the increased presence of myostatin alters osteocyte-
derived exosomal miRNAs, whose change results in inhibition
of osteoblast activity and/or promotion of osteoclast activity.
To test these hypotheses, osteocytic cells, Ocy454, were chal-
lengedwithmyostatin and, several possible effects ofmyostatin
on osteoblast and osteoclast biology were determined. Specifi-
cally, the studies performed included the expression of bone
metabolism-related genes, protein, andmiRNA inOcy454 par-
ent cells and their exosomes, differentiation of the osteoblast
and osteoclast when co-culturedwith osteocytic exosomes, and
relationship of the osteocytic exosome-mediated effects to
the Wnt signaling pathways. Our findings demonstrate a
previously unidentified role of osteocyte-derived exosomal
miR-218 in myostatin-mediated inhibition of osteoblast dif-
ferentiation and thus reveal a novel mechanism of muscle-
bone communication.
Results
Myostatinmarkedly increased the expression of SOST, DKK1,
and RANKL in Ocy454 cells
To address as to whether myostatin has a direct impact on
osteocytes, Ocy454 cells were treated with 100 ng/ml recombi-
nant myostatin protein or vehicle for 48 h, and total cellular
RNA was isolated. Quantitative real-time PCR analysis was
used to measure the levels of SOST, DKK1, RANKL, and OPG
mRNA expression, and changes in expression of these genes in
myostatin-treated Ocy454 cells were compared with those of
vehicle-treated control cells. Dramatic increases were observed
in mRNA expression of SOST, DKK1, and RANKL in response
to themyostatin treatment by280% (p 0.001),140% (p
0.01), and176% (p 0.001), respectively (Fig. 1B). Myostain
increased sclerostin protein levels by 71% (p  0.001) (Fig.
1C). Thus, myostain positively modulates the expression of
sclerostin at transcriptional and translational levels in Ocy454
cells.
Myostatin inhibited expression ofmiR-218 in Ocy454 parent
cells and released exosomes
The simultaneous, coordinated up-regulation in osteocytes
bymyostatin of SOST andDKK1,Wnt inhibitors, suggests that
3 P. Veno, M. Prideaux, V. Dusevich, L. Bonewald, and S. Dallas, unpublished
data.
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a master regulator might be responsible. Because the miR-218
gene stimulates the Wnt pathway and promotes the differenti-
ation of undifferentiated bone marrow cells by the inactivation
of SOST andDKK2during osteoblast differentiation (40), levels
of miR-218 gene in Ocy454 cell that are altered in response to
the myostatin were investigated. Interestingly, the expression
of the miR-218 in myostatin-treated Ocy454 cells displayed a
significant decrease by18% (p 0.05) compared with that in
cells treated with vehicle (Fig. 2A). As such, myostatin appears
to suppress the level of expression of the miR-218 gene, result-
ing in an increase in osteocyte SOST gene expression.
Exosomes containing miRNAs are thought to be critical for
cell-cell communication. Thus, studying the osteocyte-derived
exosomal miRNA can indicate what cellular signals from the
osteocytic parent cells send to the neighboring cells, such as
osteoblasts and osteoclasts. Therefore, levels of osteocyte-de-
rived exosomal miR-218 gene expression were examined.
Ocy454 cells were treated with 100 ng/ml myostatin protein or
vehicle for 48 h, as performed in the previous experiment, and
exosomes released from cultured medium of the Ocy454 cells
were then extracted by sequential centrifugation.
Serial assays were performed to confirm that the purified
osteocyte-derived products were indeed exosomes. CD63 is a
known protein marker of exosomes that is present on the sur-
face of the exosome membrane (37, 51, 52). Western blot anal-
ysis revealed that levels of CD63 protein in exosomal fractions
is 3–4-fold higher than those in cellular fraction (the parent
cells) (Fig. 2B), suggesting an enrichment of CD63 protein
expression in the isolated exosomes. Electron microscopy was
used to examine morphology and structure of the exosomes
obtained, which exhibited a typical morphology: round,
roughly 50–100 nm in diameter, and cup-shaped (Fig. 2C). In
parallel, the isolated exosomes were positively stained by
immunogold using an antibody against CD63 (Fig. 2C). Addi-
tionally, cellular and exosomal RNA profiles were examined by
the Agilent Bioanalyzer. The electropherograms of exosomal
RNA had a distinct RNA profile compared with cellular RNA;
the exosomal profile had significantly diminished 18S and 28S
ribosomal RNA, indicating that purified products were indeed
exosomes and not integral components of the parent cells
(Fig. 2D).
Myostatin led to a reduction in levels of osteocyte-derived
exosomal miR-218 in a time-dependent manner (supplemental
Fig. 1). Consistent with the changes in the parent cells, exo-
somes obtained from Ocy454 cells after myostatin treatment
for 48 h altered expression of miR-218 (40%; p  0.01) and
SOST genes (202% p 0.05) compared with those from con-
trol cells treated with vehicle (Fig. 2E).
Themyostatin-modified osteocytic exosomes inhibited
osteoblastic differentiation inMC3T3 cells
Whether osteocytic exosomes can directly influence differ-
entiation of osteoblasts was investigated. The questionwas first
addressed as to whether osteocyte-derived exosomes can be
taken up by recipient cells-ostoblastic MC3T3 cells. After pre-
treatment with either myostatin or vehicle for 48 h, osteocyte-
derived exosomes were isolated and labeled with PKH67 dye
(green) and then added to cultures of MC3T3 cells for 30 min.
In parallel, MC3T3 cells were preincubated with Texas Red-
transferrin (red) to label early endosomes. Afterward, the
MC3T3 cells were co-cultured with the PKH67-labeled exo-
somes or the PKH67-PBS control (containing no exosomes);
the uptake was visualized by fluorescence microscopy. Confo-
cal microscopy image showed evident uptake of the exosomes
into early endosomes of MC3T3 cells as indicated by an
increase of fluorescent intensity for PKH67 (Fig. 3, A, a–c)
Figure 1. Effects of myostatin on SOST, DKK1, RANKL, and OPG mRNA and/or protein expression in Ocy454 cells. A, a schematic diagram illustrating
experimental procedures employed. B and C, Ocy454 cells were differentiated for 12 days and then treated with 100 ng/ml myostatin or vehicle for 48 h. B,
levels of SOST, DKK1, RANKL, andOPGmRNAweredeterminedby real-timePCR.C, levels of SOSTproteinwere determinedbyWesternblotting. Images shown
in C (a) are representative of Western blot analysis. Data shown are the mean values S.E. for three separate determinations. **, p 0.01; ***, p 0.001.
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compared with MC3T3 cells co-cultured with the PKH67-PBS
control (Fig. 3A, d). As early as 5 min after incubation, PKH67
was detected in early endosomes, suggesting a rapid uptake
(supplemental Fig. 2). Internalization of exosomes is primarily
an event in cytoplasm, as manifested by a distinct pattern of
PKH67 staining in cytoplasm, which is in contrast to 7-amino-
actinomycin D (7-ADD) staining in nuclei.
Using the same co-culture approach, the effect of myostatin-
modified osteocytic exosomes on the differentiation ofMC3T3
osteoblastic precursor cells in the presence of ascorbic acid and
-glycerophosphate was tested. The degree of osteoblastogenic
differentiation ofMC3T3 cells was determined by counting the
number of cells that were positively stained for CFU-F; expres-
sion levels of pro-differentiation factors Runx2 and osteocalcin
were also examined. A 3-day incubation of MC3T3 with exo-
somes isolated from osteocytes that were pretreated with
myostatin (100 ng/ml) significantly reduced the number of
CFU-F-positive-staining colonies (Fig. 3D, p  0.05) and
down-regulated Runx2 (p 0.05) and osteocalcin (p 0.01)
mRNA expression (Fig. 3E) as well as Runx2 protein (Fig. 3F,
p  0.001) at day 10 compared with those of MC3T3 cells
when incubated with control osteocytic exosomes.
Down-regulation ofWnt signaling contributed to the
inhibition of osteoblastic differentiation by themyostatin-
modified osteocytic exosomes
The molecular basis through which osteocytic exosomes
mediate osteoblast differentiation was investigated. The effects
of osteocytic exosomes on the Wnt/-catenin signaling path-
way, that is an important cascade controlling osteoblast activ-
ity, bone formation, and skeletal adaptation, were examined.
Myostatin-modified osteocytic exosomes robustly reduced
mRNA levels of activated Wnt signaling Tcf7 (Fig. 4A, a, p 
0.05) while significantly increasing mRNA expression of other
Wnt-related genes SOST (p  0.05) and RANKL (p  0.05)
(Fig. 4A, b and c) compared with those in control MC3T3 cell
cultures. Levels of active -catenin protein were examined
using antibodies against active-catenin (53), which is dephos-
phorylated at the Ser37 and Thr41 sites. Western blot studies
revealed that levels of activated -catenin protein were signifi-
cantly reduced by myostatin-modified osteocytic exosomes
(Fig. 4B, a and b; p 0.05).
Because intracellular -catenin fate is determined by GSK3
enzyme-mediated proteasome ubiquitination (54), the effect of
Figure 2.Myostatin inhibitedmiR-218 expression inOcy454parent cells and their exosomes.As shown in Fig. 1A, Ocy454 cellswere differentiated for 12
days and then treated with 100 ng/ml myostatin or vehicle for 48 h followed by extraction of total RNA fromOcy454 parent cells or the isolation of exosomes
released form Cyc454 cells. A, levels of cellular miR-218 in Ocy454 parent cells were determined by real-time PCR. B, the Western blot showed that CD63
proteins are enriched in isolated exosomecomparedwith that in cellular protein lysate.C, electronmicroscopy analysis of exosomes;a, exosomeswere stained
with uranyl acetate (EM (negative staining));b, exosomeswere labeledwith 10-nm immunogoldusing antibody against exosomalmembranemarker CD63 and
stained with uranyl acetate (Immunogold EM (CD63)). Exosomemorphology was then visualized using electronmicroscope Hitachi H7000. D, isolated cellular
or exosomal RNA was analyzed using a Bioanalyzer. The results showed the absence of the ribosomal RNA peaks (18S and 28S rRNA) in exosomal RNA
comparedwith that of cellular RNA. E, levels ofmiR-218 andSOSTmRNA inexosomesproducedbyOcy454 cellsweredeterminedby real-timePCR.Data shown
are mean values S.E. for three separate determinations. *, p 0.05 and **, p 0.01.
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myostatin-modified osteocytic exosomes on GSK3 activity by
measuring the protein levels of phospho-GSK3 at Tyr216,
which is an activated phosphorylation site, was tested. An
increase in phosphorylation of GSK-3  at Tyr216 was observed
in theMC3T3 cells treated withmyostatin-modified osteocytic
exosomes, indicating an activation of GSK3 activity (p 0.001)
that is associatedwith inactivation of-catenin activity (Fig. 4B,
a and b). Collectively, the cellular andmolecular evidence indi-
cates that myostatin-modified osteocytic exosomes down-reg-
ulate Wnt signaling and, as a result, inhibit osteoblastic differ-
entiation and activity.
Expression of exogenousmiR-218 reversed osteocytic
exosome-mediated effects in osteoblasts
As previously demonstrated, the findings that myostatin
inhibits expression of osteocyte-derived exosomal miR-218
(Fig. 2C) and that co-culturing myostatin-modified osteocytic
exosomes with MC3TC cells suppresses differentiation of
osteoblasts (Fig. 3) led us to postulate that osteocyte-derived
exosomal miR-218 may play a key role in the regulation of
osteoblast activity. To test this possibility, the effects of expres-
sion of exogenous miR-218 on osteocytic exosome-mediated
osteoblast differentiation were evaluated inMC3T3 cells. Con-
sistent with the inhibitory effects of miR-218 in SOST gene in
MC3T3 cells (40), lentiviral expression of exogenous miR-218
dramatically suppressed mRNA expression of SOST by 2-fold
in 2 osteocyte-like cell lines, Ocy454 cells and IDG-SW3 cells,
confirming the efficacy of viral miR-218 on inhibiting SOST
gene expression (Fig. 5A, a and b).
Consistent with our previous observation, myostatin-modi-
fied osteocytic exosomes demonstrated a similar inhibition of
Runx2 (35%, p  0.001) and osteocalcin (28%, p  0.05)
mRNA expression and up-regulation of SOSTmRNA (180%,
p  0.01), whereas viral expression of miR-218 markedly
increased Runx2, osteocalcin, and OPGmRNA expression and
decreased SOST mRNA as well as increasing levels of Runx2
Figure3. Themyostatin-modifiedosteocytic exosomeswere internalized intoMC3T3cells, inhibitingosteoblasticdifferentiation.As shown in Fig. 1A,
Ocy454 cells were differentiated for 12 days and were treated with 100 ng/ml myostatin or vehicle for 48 h followed by the isolation of exosomes that are
released form Cyc454 cells. MC3T3 cells were then co-cultured with the myostatin-modified osteocytic exosomes for 48 h. A and B, uptake of osteocytic
exosomes byMC3T3 cells. 10g of the PKH67-labeled osteocytic exosomes or a PKH67-PBS control were added into per 75,000MC3T3 cells and incubated at
37 °C for 30 min. The uptake of the fluorescently labeled exosomes by MC3T3 cells was detected with confocal fluorescence microscopy. PKH67 (green) was
used to label theexosomes. TexasRed-transferrin (red, inA) or 7-AAD (red, inB)wasused todetect theearly endosomesand thenucleus (red) of theMC3T3 (red),
respectively. PKH67exosomes (green)were rapidly internalized into early endosomes labeledwith TexasRed-transferring (yellow is indicativeof co-localization
of green and red). The arrows indicate co-localization; the asterisks indicate no co-localization. C–E, co-culturingmyostatin-modified osteocytic exosomeswith
MC3T3 cells inhibits osteoblastic differentiation. C, representative images showing alkaline phosphatase staining (CFU-F) of cultures of MC3T3 cells and cell
counts of alkaline phosphatase-positive cells. D, changes in mRNA levels of Runx2 and osteocalcin in MC3T3 cells were determined by real-time PCR. E,
quantification of Runx2protein content in cell lysate fromMC3T3 cells assessedby immunoblot analysis (inset). Data are expressed as themean S.E. for three
separate determinations. *, p 0.05; ***, p 0.001 versus indicated group.
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protein by 76% (p  0.001), 85% (p  0.001), 70% (p 
0.001),71% (p 0.01), and45% (p 0.05) when compared
with those ofmiR-control (Fig. 5B). The extent of these changes
is all above or close to the levels of those of mRNA/protein
observed in control cells, indicating a complete reversal of
inhibitory effects on osteoblast differentiation that resulted
from incubation with myostatin-modified osteocytic exo-
somes. Moreover, viral expression of miR-218 completely
reversed the reduction of active -catenin protein expression
(p 0.05) inMC3T3 cells induced by the treatment of myosta-
tin-modified osteocytic exosomes (Fig. 5, C and D). The afore-
mentioned effects were concurrent with inactivation of GSK3
activity, as reflected by decreased protein levels of phospho-
GSK3 at Tyr216 (p 0.05) (Fig. 5, C and D).
Themyostatin-modified osteocytic exosomes had no direct
effect on osteoclastic differentiation
To test whether myostatin-modified osteocytic exosomes
play a role in osteoclastic differentiation, the ability of oste-
oclasts to take up exosomes was investigated. Similar to the
uptake of osteocytic exosomes by osteoblasts (Fig. 3, B and C),
RAW 264.7 cells were able to rapidly take up the osteocytic
exosomes into early endosomes at 5 and 30min after co-cultur-
ing (supplemental Fig. 3 and Fig. 6A). The internalization of
exosomes in RAW 264.7 cells occurred predominantly in cyto-
plasm (Fig. 6B).
After preculture with RANKL for 4 days, RAW 264.7 cells
were further co-cultured with myostatin-modified osteocytic
exosomes or osteocytic exosomes without anymodification for
two additional days. Unlike to the effect observed in the osteo-
blast, myostatin-modified osteocytic exosomes did not affect
the osteoclastogenic differentiation as indicated by no change
in the number of TRAP-positive colonies by TRAP staining
(Fig. 6C). This was associated with no changes in the RANKL-
induced stimulation of osteoclast markers of TRAP, calcitonin
receptor (Calcr), and integrin 3 as determined by real-time
PCR (Fig. 6D). Thus, in contrast to the negative biological
impacts on osteoblasts, themyostatin-modified osteocytic exo-
somes do not appear to exert any direct effect on the differen-
tiation of osteoclasts.
Discussion
Using the myokine myostatin as a probe, this study investi-
gated howmuscle-released products interact with bone cells to
influence their function.One of our goals was to provide insight
into the interaction of muscle and bone to coordinate cellular
and molecular function, with resultant changes in bone mass.
Here, we report for the first time that in response to myostatin,
Figure 4. Co-culturingMC3T3 cells with themyostatin-modified osteocyte-derived exosomes inactivatedWnt signaling. As shown in Fig. 1A, Ocy454
cellswere differentiated for 12 days andwere treatedwith 100 ng/mlmyostatin or vehicle for 48 h followedby the isolation of exosomes released formOcy454
cells. MC3T3 cells were then co-culturedwith themyostatin-modified osteocytic exosomes for 48 h. A, changes inmRNA levels ofWnt signaling-related genes
Tcf7, SOST, RANKL, andDKK2 inMC3T3 cells were determined by real-time PCR. B, Western blottingwas performed on total proteins fromMC3T3 cells. Images
shown in (Ba) were representativeWestern blotting. Bb, blots in (Ba) were quantified by scanning densitometry and normalized relative to-tubulin. Data are
expressed as the mean S.E. for three separate determinations. *, p 0.05; ***, p 0.001 versus the indicated group.
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osteocytes react to produce greater amounts of SOST, RANKL,
andDKK1, each of the products an important regulator in bone
remodeling. Second, our study establishesmyostatin as the first
signaling product released by muscle that is able to directly
target osteocyte-derived exosomes to regulate content of miR-
218. Specifically, myostatin inhibits expression of miR-218 in
the exosomes released from the osteocytes; the osteocyte-de-
rived exosomes that contain reduced levels of miR-218 may
then be transferred to osteoblasts to inhibit osteoblastic differ-
entiation and, perhaps, bone formation. Furthermore, our data
suggest that the inhibitory effect of myostatin-mediated sup-
pression of osteocytic exosomal miR-218 on osteoblast func-
tion is associated with the down-regulation of the canonical
Wnt signaling pathway. Of note, the suppressive effect of myo-
statin-modified osteocytic exosomes on osteoblast differentia-
tion is completely counteracted by the expression of exogenous
miR-218 through the down-regulation of SOST. These findings
suggest a novelmechanismunderlyingmuscle-bone communi-
cation to maintain homeostasis of the local musculoskeletal
environment via osteocytes, at least in part, by the generation
and release of miRNA inside of exosomes.
Our findings demonstrate that the treatment of osteocyte
cells withmyostatin leads to significant increases in the expres-
sion of SOST andDKK1, twoWnt signaling inhibitors, suggest-
ing that myostatin may have an inhibitory impact on osteoblast
activity and bone formation indirectly through products
released by osteocytes. Whether there is a direct effect of myo-
statin on osteoblasts is unclear (28, 29). Literature regarding
whether other muscle-secreted factors have direct effects on
osteoblasts remains controversial. A recent study showed that
direct incubation of preosteoblastic MC3T3 cells with condi-
tionedmedium from cultures of contractedmuscle cells had no
effect on proliferation, metabolic activity, or mineralization of
osteoblasts,4 implying the absence of direct effect of muscle-
produced products on osteoblasts in response to an exercise
regimen. In contrast, irisin, a myokine generated by skeletal
muscle during exercise, has been reported to directly enhance
osteoblast differentiation, promote bone formation, and
increase bone mass (25). Nonetheless, our evidence provides
novel insight into how myostatin indirectly regulates bone for-
mation via osteocytes. In addition, we have shown that myosta-
tin significantly increases expression of RANKL in osteocytes,
strongly suggesting that myostatin may indirectly promote
osteoclast differentiation, activity, and viability, presumably
associated with enhanced bone resorption.
Our findings addressing the role of myostatin on osteoblast
activity indirectly through osteocytes are consistent with a
recent observation in which factors secreted from contracted
muscle had indirect effects on osteoblasts through the stimula-
tion of prostaglandin E2 production and reduction of sclerostin
in osteocytes; however, it remains largely unknown what fac-
tors are exactly released from the contracted muscle.4 In this
regard our study establishes myostatin as the first signaling
4 H. Kondo, N. Zhao,M. Prideaux, Y. Kitase, J. Vallejo, S. Dallas, M. Brotto, and L.
Bonewald, unpublished data.
Figure 5. Expression of exogenous miR-218 reversed the inhibitory effects of myostatin-modified osteocyte-derived exosomes on osteoblastic
differentiation. As shown in Fig. 1A, Ocy454 cells were differentiated for 12 days and were treated with 100 ng/ml myostatin or vehicle for 48 h followed by
the isolation of exosomes released formCyc454 cells. MC3T3 cells were then co-culturedwith themyostatin-modified osteocytic exosomes in the presence of
lentivirus-mediated exogenous expression of miR-218 or scramble control plasmid (miR-C) for 48 h. Total RNA or protein was isolated on day 3 and subjected
to real-timePCRorWestern blot analysis, respectively.A, efficacy of exogenous expressionofmiR-218on inhibiting SOSTmRNAexpression inOcy454 cells and
IDG-SW3 cells. B, changes inmRNA levels of RunX2, osteocalcin, andOPG inMC3T3 cellswere determinedby real-time PCR.C, Western blottingwas performed
on total proteins from MC3T3 cells. Images shown were representative Western blottings. D, blots in C were quantified by scanning densitometry and
normalized relative to -tubulin. Data are expressed as the mean  S.E. for three separate determinations. *, p  0.05; **, p  0.01, ***, p  0.001 versus
indicated group.
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product released by muscle that is able to directly target osteo-
cytes and osteocyte-derived exosomal miRNA and, thereby,
influence osteoblast function. Currently, it is unclear the man-
ner in which myostatin is transported to the osteocyte that
is deeply embedded in the bone matrix. Myostatin may be
released into the general circulation to be presented to the den-
dritic processes of osteocyte protruding into vascular channels
for cellular uptake (57),5 but certainly other mechanisms may
exist to facilitate myostatin transport to the osteocyte. For
example, the transport of myostatin may occur extracellularly
through the lacunar-canalicular systemwithin the bonematrix.
Among other mechanisms, expression of SOST has been
shown to be controlled by miR-218, where miR-218 acts as an
inhibitor of SOST and a potent activator of the Wnt signaling
pathway, thus contributing to osteoblastogenesis (40). Excit-
ingly, we found that in cultured osteocytes, the expression of
miR-218 was significantly decreased by 18% upon challenge
with myostatin. The myostatin-mediated down-regulation of
miR-218 was associated with the increased levels of SOST
mRNA and protein, suggesting that myostatin acts through
miR-218 to influence SOST expression in osteocytes. Most
strikingly, exosomal miR-218 shed from osteocytes is signifi-
cantly down-regulated by myostatin by40%, a change higher
than that which occurs in the donor cells. Thus, myostain
appears to manipulate miR-218 and potentially other miRNA
gene profiles, not onlywithin the osteocyte but also in the extra-
cellular vesicles released. Future work is required to investigate
how myostatin down-regulates miR-218 at transcriptional
and/or post-transcriptional levels.
The release of osteocytic microvesicles was observed in a
recent study using live-cell imaging in a mouse model express-
ingmembrane-boundGFP specifically in osteocytes;5 however,
the biological features of osteocyte-derived microvesicles, par-
ticularly exosomes, remained ill defined. In the present study,
electron microscopy of the pellet obtained in the last centrifu-
gation by a standard differential centrifugation revealed that
Ocy454 cells secrete exosome-like microvesicles into the cul-
ture media. These vesicles are 50–100 nm in diameter, have a
cup-shaped appearance, and are positively stained with immu-
nogold-labeled CD63 antibody, consistent with previous
descriptions of exosomes (36–38, 52, 58–60). Additional
immune-blotting approaches confirmed that CD63 protein
expression is enriched in the isolated exosomes. RNA profiles
from cellular and exosomal fractionswere compared usingAgi-
lent Bioanalyzer, indicating the absence of cytoplasmic con-
tamination from donor cells and the presence of predominant
amounts of small RNA (miRNA) species in the exosomes.
These unique features are strongly confirmatory that the
microvesicles released from Ocy454 cells in this study are
indeed exosomes. To our knowledge our work is the first to
systemically characterize osteocyte-derived exosomes at mor-
phological, cellular, and molecular levels and, furthermore, to
elucidate how miRNA expression (e.g.miR-218) of osteocytic-5 P. Veno, M. Prideaux, V. Dusevich, L. Bonewald, S. Dallas, unpublished data.
Figure 6. Themyostatin-modified osteocyte-derived exosomes have no direct effect on osteoclastic differentiation. As shown in Fig. 1A, Ocy454 cells
were differentiated for 12days andwere treatedwith 100ng/mlmyostatin or vehicle for 48 h followedby the isolationof exosomes released formCyc454 cells.
RAW 264.7 cells were then co-cultured with themyostatin-modified osteocytic exosomes for 48 h. A and B, uptake of osteocytic exosomes by RAW 264.7 cells
was examined by using the approaches as described in Fig. 3, A and B. The arrows indicate co-localization; the asterisk indicates no co-localization. C and D,
co-culture of myostatin-modified osteocytic exosomes with RAW 264.7 cells had no effect on osteoclastic differentiation. C, representative images showing
TRAP staining of cultures of RAW 264.7 cells and cell counts of TRAP-positive cells.D, changes inmRNA levels of TRAP, calcitonin receptor (Calcr), and integrin
3 in RAW 264.7 cells were determined by real-time PCR. Data are expressed as the mean S.E. for three separate determinations.
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derived exosomes appears to be influenced by local environ-
mental factors.
In this study the exosome-tracking experiments demonstrate
that osteocyte-derived exosomes could be rapidly taken up by
osteoblasts. When co-cultured with osteocyte-derived exo-
somes that were pretreated with myostatin, osteoblastic differ-
entiation ofMC3T3 cells was inhibited, including reductions in
the number of CFU-F-positive cells and decreased levels of pro-
differentiation factors Runx2 mRNA and protein as well as
osteocalcin mRNA. These changes were accompanied by
the inactivation of Wnt signaling activity, as evidenced by
decreased Tcf7 and up-regulated SOST and RANKL as well as
diminished levels of active -catenin and increased phospho-
GSK3 at Tyr216. It has been reported that in addition to tar-
geting SOST, osteoblast-derived miR-218 also inhibits DKK2
and sFRP2 in cultured MC3T3 cells (40). It is unclear why the
expression of DKK2 and sFRP2 were not altered in osteocytes
by myostatin or in MC3T3 cells by myostatin-modified osteo-
cytic exosomes (data not shown). It is possible that differences
in other factors (e.g. other miRNAs, but not miR-218) targeting
DKK2 and sFRP2 or other unknown effects of myostatin might
have contributed to the distinct outcomes in two types of bone
cells in their response tomiR-218. Collectively, our data suggest
that the osteocyte-derived exosomes containing reduced levels
of miR-218 upon myostatin treatment could be transferred to
osteoblasts to inhibit osteoblastic differentiation and perhaps
bone formation, most likely through the down-regulation of
canonical Wnt signaling pathway. Hence, this work represents
the first study to characterize not only the uptake of osteocytic
exosomes by osteoblast cells but also the consequence of such
an event; that is, the modulation of osteoblast activity.
Considering the role of osteocyte-derived exosomalmiR-218
in the regulation of osteoblastic differentiation, overexpression
of this miRNA in osteoblasts is expected to exert beneficial
effects on the differentiation of osteoblastic cells. Thus, the
therapeutic effect of osteoblasts-targeted miR-218 activation
by transducing lentiviral miR-218 was considered. Myostatin-
modified osteocytic exosomes significantly down-regulated
osteoblast activity inMC3T3 cells, and such an inhibitory effect
was prevented by the forced expression of miR-218, through a
mechanism involving miR-218-mediated inhibition of SOST.
Down-regulation of osteoblast activity occurred in association
with the resurgence of Wnt signaling activity, as reflected by
up-regulated levels of active -catenin and increased phospho-
GSK3 at Tyr216. These findings further indicate that miR-218
plays a key role in myostatin-modified osteocytic exosomes in
the control of osteoblastic differentiation through regulation of
SOST. This mechanism suggests that miR-218 may be a thera-
peutic target and that the enhancement of miR-218 expression
in osteocytes may promote osteoblast activity and, ultimately,
increase bone formation.
Despite the profound inhibition of osteoblastic differentia-
tion, the uptake of myostatin-modified osteocytic exosomes by
osteoclasts has no direct effect on osteoclast activity. There was
no change in osteoclastogenic differentiation as determined by
TRAP staining and no changes in gene expressions of osteoclast
markers TRAP, calcitonin receptor, and integrin 3. This effect
is partially explained by the absence of change in RANKL
mRNA expression in the osteocyte-derived exosomes in
response to myostatin treatment (supplemental Fig. 4). These
findings taken together with a recent observation that myosta-
tin did not directly regulate expression of RANKL and M-CSF
in mouse synovial fibroblasts and osteoblasts (61) suggests that
the effect of myostatin on osteoclast differentiation, if any,
should be attributable to either the paracrine action from other
sources or the direct control over osteoclasts in an osteoblast or
osteocytic exosome-independent mechanism. The former pos-
sibility was supported by our findings. First, myostatin signifi-
cantly increased expression of RANKL mRNA in osteocytes
and, presumably, increased soluble RANKL protein that was
able to traffic to osteoclasts and indirectly promote osteoclast
activity. Another possibility is that the uptake of themyostatin-
modified osteocytic exosomes by osteoblasts greatly increased
expression of RANKL (Fig. 4), thereby indirectly affecting oste-
oclast activity.We note that in the experiments presented here,
osteocytes remain viable when challengedwith 100 ng/mlmyo-
statin, as assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (data not shown). There-
fore, this study does not exclude the possibility that osteocytic
exosomes might have a direct role on osteoclasts in other
pathophysiological conditions. Consistent with this notion,
osteocytic apoptotic bodies released during apoptosis have
been shown to promote osteoclastogenesis, whereas factors
present in the soluble fraction derived from both necrotic and
healthy osteocytes were incapable of promoting osteoclasto-
genesis (62). In addition, myostatin has been recently reported
to strongly accelerate RANKL-mediated osteoclast formation
in in vitro cultured bone marrow-derived macrophages by a
mechanism through Smad2-dependent regulation of nuclear
factor of activatedT-cells (NFATC1) (Fig. 7), suggesting a direct
effect of myostatin on osteoclasts (61). Taken together, the
findings from the present study define a direct action of myo-
statin on osteocytes to promote RANKL production as a novel
mechanism of indirectly controlling osteoclast activity and
bone resorption in an osteoblast or osteocytic exosomes-inde-
pendent manner.
In summary, this study has defined novel mechanisms
through which muscle exerts regulation of bone cell function
(Fig. 7). Our findings provide the first in vitro evidence that
osteocyte-derived exosomal miRNA works as a signal complex
by which, in response to a message from muscle (e.g. myosta-
tin), bone cells might respond and communicate to ensure that
the mass and function of bone is regulated appropriately in
concert with that of muscle. Future study will define whether
the putativemuscle-bone interaction that has been suggested in
the present study may actually exist in the physiological envi-
ronment.Our study supports the notion that inhibition ofmyo-
statin serves a dual benefit in the protection ofmuscle and bone
against loss in osteopenia and sarcopenia (28). The regulation
of the miR-218 gene in osteocytes emerges as an interesting
research direction because miR-218 responds to a muscle-re-
leased hormone and, in turn, influences osteoblast activity by
modulation of SOST andWnt signaling, possibly among others
signaling pathways. Thus, the manipulation of miR-218 in
osteocytes can be considered as a future therapeutic strategy for
the treatment of bone loss associated with the age-related sar-
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copenia, menopause, and immobilization (e.g. spinal cord
injury, stroke, and other conditions associated with restricted
weight-bearing activity). In a future study it will be relevant to
determine whether other myokines, such as irisin and IL-6,
have similar direct effects to that of myostatin on the osteocyte
and its exosomes to influence the osteoblast and/or osteoclast.
In addition, future work to characterize changes in osteocyte-
derived exosomal miRNA profiles in response to muscle hor-
mones will identify additional miRNA candidate genes in the
regulation of function of the osteocyte with consequences to
bone homeostasis.
Experimental procedures
Cell culture and treatment
Mouse osteocyticOcy454 cells weremaintained as described
previously (63). To differentiate osteocytic phenotype, Ocy454
cells were seeded in a 10-cm culture plate at a density of 1 106
and cultured at 33 °C for 48 h. Cells were then cultured in 37 °C
for an additional 10 days. At day 12, Ocy454 were treated with
myostatin (100 ng/ml; R&D Systems, 788-G8-010) or PBS
(vehicle) for 48 h followed by the isolation of exosome in con-
ditioned medium, cellular total RNA, and proteins (as
described in greater detail below). The dose of myostatin fol-
lows that utilized by previous studies (29, 64). IDG-SW3 cells
were cultured as described previously (65, 66). For experimen-
tal treatment and co-culturing studies, FBS was depleted of
exosomes by ultracentrifugation at 100,000  g for 4 h at 4 °C
followed by filtration through a 0.22-m filter (Millipore) to
sterilize.
For osteoblastogenesis, 2.5  104 MC3T3-E1 (subclone 4)
cells, osteoblastic precursor cells were seeded and cultured in
12-well tissue culture plates as described in greater detail in the
supplemental Materials and Methods At day 8, MC3T3 cells
were co-cultured with myostatin-modified or control exo-
somes for 48 h followed by staining multicellular fibroblastoid
colonies (CFU-F) using an alkaline phosphatase kit permanufa-
cturer’s recommendations (Sigma). For osteoclastogenesis, 2
103 RAW264.7 cells were seeded and cultured in 96-well tissue
culture plates as described in greater detail in the supplemental
Materials andMethods. At day 5, RAW264.7 cells were co-cul-
tured with myostatin-modified or control exosomes for 48 h
followed by TRAP staining using a kit (Sigma) per the manufa-
cturer’s instruction. A parallel set of osteoblasts or osteoclast
cultures was used to extract total RNAor proteins, respectively.
For lentivirus packaging, 293TN cells were transfected
with Lenti-miR218-2 (PMIRH218–2PA-1) or scramble control
plasmid (miR-C, PMIRH000PA-1) plus the pPACKH1TM
Packaging Plasmid mix (System Biosciences) using the Lipo-
fectamine LTX with Plus Reagent (Thermo Fisher Scientific).
Supernatant was collected and concentrated 48 h post transfec-
tion. For viral transduction, targeted cells were infected with
concentratedmiR-218 or scramble lentiviral supernatant (mul-
tiplicity of infection 4) in the presence of 5 g/ml Polybrene.
Biological assays were performed 48 h post transduction. The
methods are described in greater detail in the supplemental
Materials and Methods.
Isolation of exosomes
A sequential centrifugation procedure was used to isolate
exosomes as described previously (38, 59). Briefly, conditioned
cell culture medium was prepurified by centrifugation at
2000  g for 30 min at 4 °C to remove floating cells, and the
supernatant was collected and filtered through a 0.2-m
syringe filter (Millipore) to remove cell debris. Exosomes were
pelleted in a two-step ultracentrifugation using a Ti 50.2 rotor
(Beckman) at 100,000  g for 70 min at 4 °C with 1 PBS wash
between 2 ultracentrifugations. The pelted exosomes were
resuspended in PBS or in lysis buffer and stored at 80 °C for
experimental analysis.
Western blot analysis
Proteins from cultured cells and purified exosomeswere sep-
arated on a denatured SDS-polyacrylamide gel andwere immu-
nologically detected as described in greater detail in the supple-
mental Materials and Methods.
Electronmicroscopy
Exosomes from Ocy454 cells were fixed in 2.5% glutaralde-
hyde, loaded onto Formvar carbon-coated copper grids (Elec-
tronMicroscopy Sciences, FCF-200-Cu), washed, and followed
by negative staining with 2% uranyl acetate. The exosomes on
grids were viewed using a Hitachi H7000 electron microscope
Figure 7. A schema of the putative mechanisms by which myostatin may influence the function of bone cells. Myostatin influences osteoblastic
differentiation through the osteocyte and its release of exosomal miR-218 in a mechanism that involves the activation of SOST and its inhibition of the Wnt
signaling pathway. Additionally, myostatin promotes RANKL production in osteocytes and, in turn, has the potential to increase osteoclast differentiation,
activity, andviability.Wenote thatmyostatinhasbeen recently reported todirectly accelerate RANKL-mediatedosteoclast formationby amechanism through
transcription factor Smad2-dependent regulation of NFATC1 (nuclear factor of activated T-cells; Ref. 61). Whether there is a direct effect of myostatin on
osteoblasts remains to be determined.
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at 75 kV. The electron microscope was equipped with an AMT
Advantage HS digital camera (Danvers), andmicrographs were
recorded digitally as described previously (60). In a parallel
study, the same procedures were performed except that before
negative staining with uranyl acetate, the fixed exosomes in the
copper grids were immunolabeled with anti-CD63 antibody
followed by a 10-nm gold-labeled secondary antibody (Sigma).
The methods are described in greater detail in supplemental
Materials and Methods.
Visualization of exosome uptake
Isolated osteocytic exosomes were labeled with PKH67
Green Fluorescent Cell Linker Kit for General Cell Membrane
Labeling (Sigma) according to the manufacturer’s protocol
(67). Before co-culture, MC3T3 cells or RAW264.7 cells were
preincubated with 25 g/ml Texas Red-transferrin (Life Tech-
nologies) for 30 min at 37 °C to label early endosomes (68).
MC3T3 cells or RAW264.7 cells were then co-cultured with 10
g of the PKH67-labeled exosomes or the PKH67-PBS control
and incubated for 5 or 30 min at 37 °C. Uptake of exosomes by
these cells was stopped by washing with 0.1% sodium azide
PBS followed by fixation in 4% formaldehyde, mounting to
Vectashield (Vector Laboratories), and visualizing with a fluo-
rescencemicroscope (Zeiss Axioplan 2, Carl Zeiss). In a parallel
study, instead of using Texas Red-transferrin to label early
endosomes, MC3T3 or RAW264.7 cells were directly incu-
bated with PKH67-labeled exosomes or the PKH67-PBS con-
trol. The binding of the exosomes to these cells was then visu-
alized with a fluorescence microscope with 3% 7-ADD (BD
Biosciences) to label nuclei. The methods are described in
greater detail in the supplemental Materials and Methods.
RNA isolation and analysis of gene expression by quantitative
PCR
Total RNA was isolated using themirVana miRNA isolation
kit (Invitrogen) according to the manufacturer’s instructions.
The quality of the RNA samples was assessed with an Agilent
Bioanalyzer. For determination of mRNA levels,1 g of total
RNAwas used to generate a cDNA library with aHigh Capacity
cDNA Reverse Transcription kit (Applied Biosystems). For
determination of miRNA levels, cDNA was synthesized from 1
g of total RNA using the specific primers provided with the
TaqMan miRNA assays (Life Technology) according to the
protocol provided by themanufacturer. After dilution of cDNA
libraries into water, levels of specific mRNAs or miRNAs were
determined by Taqman Assay On Demand probesets (Applied
Biosystems) or SYBR quantitative PCR (StepOnePlus, Life
Technologies) using an ABI 7500 real time PCR machine.
Primer sequences are available upon request. Changes in gene
expression were calculated using the 2Ct method using 18S
RNA or U6 snRNA for normalization (69). The methods are
described in greater detail in the supplemental Materials and
Methods.
Statistics
Data is expressed as themean S.E.; the number of indepen-
dent samples (n) is provided in the legend of each figure. The
statistical significance of differences among means was tested
using one-way analysis of variance and a Newman-Keuls post
hoc test to determine the significance of differences between
individual pairs ofmeans using a p value of 0.05 as the cutoff for
significance. Statistical calculations were performed using
Prism 4.0c (GraphPad Software, La Jolla, CA).
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